Optimization of Benzoxazinorifamycins to Minimize hPXR Activation for the Treatment of Tuberculosis and HIV Coinfection-Reference-Cited by-同舟云学术

Optimization of Benzoxazinorifamycins to Minimize hPXR Activation for the Treatment of Tuberculosis and HIV Coinfection

Published:2022-06-30 Issue:8 Volume:8 Page:1408-1421
ISSN:2373-8227
Container-title:ACS Infectious Diseases
language:en
Short-container-title:ACS Infect. Dis.

Author:

Ashkar Shireen R.¹^ORCID,Rajeswaran Walajapet¹²,Lee Pil H.¹²,Yeomans Larisa¹,Thrasher Claire M.¹,Franzblau Scott G.³^ORCID,Murakami Katsuhiko S.⁴,Showalter Hollis D.¹^ORCID,Garcia George A.¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109-1065, United States

2. Vahlteich Medicinal Chemistry Core, University of Michigan, Ann Arbor, Michigan 48109-1065, United States

3. Institute for Tuberculosis Research, University of Illinois, Chicago, Illinois 60612-7231, United States

4. Department of Biochemistry and Molecular Biology, Pennsylvania State University, State College, University Park, Pennsylvania 16801, United States

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Infectious Diseases

Link

https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.1c00635

Reference47 articles.

1. World-Health-Organization. Global Tuberculosis Report 2021, 2021.

2. Strong In Vitro Activities of Two New Rifabutin Analogs against Multidrug-Resistant Mycobacterium tuberculosis

3. The challenge of new drug discovery for tuberculosis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimization of Benzoxazinorifamycins to Improve Mycobacterium tuberculosis RNA Polymerase Inhibition and Treatment of Tuberculosis;ACS Infectious Diseases;2022-06-30